Evidence map›Paper›PMID 28639625›Full record

ArticleNature communications2017

MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis.

Mariola Kurowska-Stolarska, Stefano Alivernini, Emma Garcia Melchor, Aziza Elmesmari, Barbara Tolusso, Clare Tange, Luca Petricca, Derek S Gilchrist, Gabriele Di Sante, Chantal Keijzer and 13 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. miRNAs and T cell-mediated Immune Response in Disease.The Yale journal of biology and medicine · 2025
    Review
  10. AXL signaling in cancer: from molecular insights to targeted therapies.Signal transduction and targeted therapy · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. AXL Inhibits Proinflammatory Factors to Relieve Rheumatoid Arthritis Pain by Regulating the TLR4/NF-Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  18. An update on epigenetic regulation in autoimmune diseases.Journal of translational autoimmunity · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 4 countries.

Mariola Kurowska-StolarskaInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Stefano AliverniniDivision of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome 00168, Italy.
Emma Garcia MelchorInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Aziza ElmesmariInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Barbara TolussoDivision of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome 00168, Italy.
Clare TangeInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Luca PetriccaDivision of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome 00168, Italy.
Derek S GilchristInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Gabriele Di SanteDivision of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome 00168, Italy.
Chantal KeijzerInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Lynn StewartInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Clara Di MarioDivision of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome 00168, Italy.
Vicky MorrisonInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
James M BrewerInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Duncan PorterInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Simon MillingInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.ORCID 0000-0003-4384-5516
Ronald D BaxterInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
David McCareyNHS Greater Glasgow and Clyde, 1055 Great Western Road, Glasgow G12 0XH, UK.
Elisa GremeseDivision of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome 00168, Italy.
Greg LemkeMolecular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, California 92037, USA.
Gianfranco FerraccioliDivision of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome 00168, Italy.
Charles McSharryInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
Iain B McInnesInstitute of Infection, Immunity and Inflammation, University of Glasgow, 120 University Place, Glasgow G12 8TA, UK.
University of Glasgow · GBUniversità Cattolica del Sacro Cuore · ITNHS Greater Glasgow and Clyde · GBSalk Institute for Biological Studies · US

Funding

Medical Research Council MR/N005813/1Versus Arthritis 19213Versus Arthritis 20816Versus Arthritis 20848
6 · The paper itself

Abstract

Current treatments for rheumatoid arthritis (RA) do not reverse underlying aberrant immune function. A genetic predisposition to RA, such as HLA-DR4 positivity, indicates that dendritic cells (DC) are of crucial importance to pathogenesis by activating auto-reactive lymphocytes. Here we show that microRNA-34a provides homoeostatic control of CD1c

Indexed as

AgedAnimalsAntigens, CD1Arthritis, ExperimentalArthritis, RheumatoidAxl Receptor Tyrosine KinaseDendritic CellsEpigenesis, GeneticGene Expression RegulationGlycoproteinsHumansMice, Inbred C57BLMice, Mutant StrainsMicroRNAsMiddle AgedProto-Oncogene ProteinsAntigens, CD1Axl Receptor Tyrosine KinaseCD1C protein, humanGlycoproteinsMicroRNAsMIRN34a microRNA, mouseMIRN34 microRNA, humanProto-Oncogene ProteinsReceptor Protein-Tyrosine Kinases

Identifiers

PMID28639625
PMCPMC5489689
OpenAlexW2613983133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.